Dopo l'orario di chiusura: 5.41

Uniqure N V (QURE)

Uniqure N V Borsa (QURE) Ultime notizie

Uniqure N V (QURE)

Uniqure N V Borsa (QURE) Ultime notizie

Acadian Asset Management LLC Sells 99,744 Shares of uniQure (NASDAQ:QURE) - MarketBeat

(QURE) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Acadian Asset Management LLC Has $2.30 Million Position in uniQure (NASDAQ:QURE) - Defense World

uniQure (NASDAQ:QURE) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Institutional owners may take dramatic actions as uniQure N.V.'s (NASDAQ:QURE) recent 11% drop adds to one-year losses - Simply Wall St

Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology - GlobeNewswire Inc.

Trading (QURE) With Integrated Risk Controls - Stock Traders Daily

uniQure N.V.’s Banking’s 100-Day Moving Average at 5.76: Will the Stock Break Through? - The InvestChronicle

Assenagon Asset Management S.A. Makes New Investment in uniQure (NASDAQ:QURE) - MarketBeat

uniQure Forecasted to Post FY2024 Earnings of ($4.84) Per Share (NASDAQ:QURE) - MarketBeat

FY2024 Earnings Forecast for uniQure Issued By HC Wainwright (NASDAQ:QURE) - Defense World

uniQure retains PT with Buy rating on gene therapy prospects - Investing.com

HC Wainwright Reaffirms "Buy" Rating for uniQure (NASDAQ:QURE) - MarketBeat

HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE) - Defense World

Is uniQure N.V. (QURE) worth investing in despite its undervalued state? - US Post News

QURE (uniQure NV) Cash From Other Investing Activities : $-366.44 Mil (TTM As of Jun. 2024) - GuruFocus.com

QURE (uniQure NV) Total Inventories : $0.00 Mil (As of Jun. 2024) - GuruFocus.com

uniQure NV (STU:UQ1) 3-Year EPS without NRI Growth Rate : -36.20% (As of Jun. 2024) - GuruFocus.com

QURE (uniQure NV) Change In Receivables : $90.64 Mil (TTM As of Jun. 2024) - GuruFocus.com

Vanguard Group Inc. Raises Position in uniQure (NASDAQ:QURE) - MarketBeat

Vanguard Group Inc. Acquires 109,740 Shares of uniQure (NASDAQ:QURE) - Defense World

uniQure (NASDAQ:QURE) Short Interest Up 20.1% in July - MarketBeat

uniQure NV (STU:UQ1) Inventory-to-Revenue : 0.68 (As of Jun. 2024) - GuruFocus.com

uniQure NV (STU:UQ1) Financial Strength : 4 (As of Jun. 2024) - GuruFocus.com

uniQure Begins Phase I/IIa Trial for Fabry Disease Treatment - TipRanks

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - GlobeNewswire

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease - StockTitan

Analysts Set uniQure (NASDAQ:QURE) Price Target at $18.60 - MarketBeat

uniQure (NASDAQ:QURE) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World

Implied Volatility Surging for uniQure (QURE) Stock Options - Yahoo Singapore News

Cantor Fitzgerald Weighs in on uniQure's FY2024 Earnings (NASDAQ:QURE) - MarketBeat

uniQure (NASDAQ:QURE) Expected to Earn FY2024 Earnings of ($3.14) Per Share - Defense World

StockNews.com Upgrades uniQure (NASDAQ:QURE) to “Sell” - Defense World

How to Take Advantage of moves in (QURE) - Stock Traders Daily

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity (QURE) - Seeking Alpha

uniQure (NASDAQ:QURE) Upgraded to "Sell" by StockNews.com - MarketBeat

Leerink Partnrs Comments on uniQure's Q3 2025 Earnings (NASDAQ:QURE) - MarketBeat

Analysts Offer Predictions for uniQure’s Q3 2025 Earnings (NASDAQ:QURE) - Defense World

The Goldman Sachs Group Increases uniQure (NASDAQ:QURE) Price Target to $10.00 - Defense World

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Simply Wall St

uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance

UniQure to cut 65% of workforce, or 300 jobs, in major restructuring (NASDAQ:QURE) - Seeking Alpha

uniQure (NASDAQ:QURE) PT Raised to $10.00 at The Goldman Sachs Group - MarketBeat

UniQure Keeps Cutting Costs With 300 More Jobs To Go - Scrip

UniQure: Q2 Earnings Snapshot - Darien Times

UniQure: Q2 Earnings Snapshot - San Antonio Express-News

UniQure: Q2 Earnings Snapshot - New Haven Register

UniQure: Q2 Earnings Snapshot - The Advocate

UniQure: Q2 Earnings Snapshot - The Washington Post

UniQure: Q2 Earnings Snapshot - San Francisco Chronicle

UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance

UniQure: Q2 Earnings Snapshot - Barchart

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update - StockTitan

Trading Day Triumph: uniQure N.V. (QURE) Ends at 7.63, a -2.24 Surge/Plunge - The Dwinnex

Get in on uniQure N.V.’s (QURE) buy-in window today! - SETE News

uniQure N.V. (QURE) deserves deeper analysis - US Post News

Genezen’s Acquisition of Gene Therapy Manufacturing Facility - Global Legal Chronicle

uniQure (NASDAQ:QURE) Sees Large Growth in Short Interest - MarketBeat

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High? - Yahoo Canada Finance

Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High? - Nasdaq

Hemophilia Gene Therapy Market Is Booming Worldwide 2024-2031 | - openPR

Simile a QURE